Loading…

Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies

Summary Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of th...

Full description

Saved in:
Bibliographic Details
Published in:Plant biotechnology journal 2013-12, Vol.11 (9), p.1029-1033
Main Authors: Ma, Julian K‐C., Christou, Paul, Chikwamba, Rachel, Haydon, Hugh, Paul, Mathew, Ferrer, Merardo Pujol, Ramalingam, Sathishkumar, Rech, Elibio, Rybicki, Edward, Wigdorowitz, Andres, Yang, Dai‐Chang, Thangaraj, Harry
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3
cites cdi_FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3
container_end_page 1033
container_issue 9
container_start_page 1029
container_title Plant biotechnology journal
container_volume 11
creator Ma, Julian K‐C.
Christou, Paul
Chikwamba, Rachel
Haydon, Hugh
Paul, Mathew
Ferrer, Merardo Pujol
Ramalingam, Sathishkumar
Rech, Elibio
Rybicki, Edward
Wigdorowitz, Andres
Yang, Dai‐Chang
Thangaraj, Harry
description Summary Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.
doi_str_mv 10.1111/pbi.12127
format article
fullrecord <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_proquest_miscellaneous_1468354080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1461339288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3</originalsourceid><addsrcrecordid>eNqN0U1LHDEYB_AgFdeXHvoFSqCXetg1yUxePLZSrSAoYs8hyT7RLJnJNJmx-O2b3bV7KAgmh4SHX_7w5EHoEyULWtfZYMOCMsrkHjqkrZBzKTj7sLu37QwdlbIihFHBxQGasZbSc6qaQ5TvwcRQQv-IxyfAzyZOgJPHQzT9iLsUwU3RZDw8mdxtVMIWevBh3DwYUso49HgJzxDTsBYuTf2YAxRs-iWGDvLjugwu9amr5RO0700s8PH1PEa_Ln88XPyc39xeXV98u5m7llE5B2upMJZKz8ECWXrnhSTENUo6YaVzlCvWMkYE48KZ1nNulVDAnHMcwDfH6Os2d8jp9wRl1F0oDmLtDNJUdP0d1fCWKPIeSpvmnClV6Zf_6CpNua-N6IYIWbfivKrTrXI5lZLB6yGHzuQXTYlez0zXmenNzKr9_Jo42Q6WO_lvSBWcbcGfEOHl7SR99_16G_kXUXWhMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067676855</pqid></control><display><type>article</type><title>Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><creator>Ma, Julian K‐C. ; Christou, Paul ; Chikwamba, Rachel ; Haydon, Hugh ; Paul, Mathew ; Ferrer, Merardo Pujol ; Ramalingam, Sathishkumar ; Rech, Elibio ; Rybicki, Edward ; Wigdorowitz, Andres ; Yang, Dai‐Chang ; Thangaraj, Harry</creator><creatorcontrib>Ma, Julian K‐C. ; Christou, Paul ; Chikwamba, Rachel ; Haydon, Hugh ; Paul, Mathew ; Ferrer, Merardo Pujol ; Ramalingam, Sathishkumar ; Rech, Elibio ; Rybicki, Edward ; Wigdorowitz, Andres ; Yang, Dai‐Chang ; Thangaraj, Harry</creatorcontrib><description>Summary Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.</description><identifier>ISSN: 1467-7644</identifier><identifier>EISSN: 1467-7652</identifier><identifier>DOI: 10.1111/pbi.12127</identifier><identifier>PMID: 24119183</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Biological Products - metabolism ; Biotechnology ; Biotechnology - economics ; Biotechnology - methods ; Developing Countries ; Drug Design ; Drug Industry - economics ; Global Health ; Humans ; Intellectual Property ; LDCs ; Licenses ; Licensing (technology) ; low income ; Molecular Farming - economics ; Molecular Farming - methods ; molecular pharming ; Pharmaceutical industry ; Pharmaceuticals ; Plants - genetics ; Plants - metabolism ; Plants, Genetically Modified ; Public health ; R&amp;D ; regulatory framework ; Research &amp; development ; resource‐poor ; socially responsible licensing ; Technology Transfer ; Technology, Pharmaceutical - economics ; Therapeutic targets ; Vaccines</subject><ispartof>Plant biotechnology journal, 2013-12, Vol.11 (9), p.1029-1033</ispartof><rights>2013 Society for Experimental Biology, Association of Applied Biologists and John Wiley &amp; Sons Ltd</rights><rights>2013 Society for Experimental Biology, Association of Applied Biologists and John Wiley &amp; Sons Ltd.</rights><rights>2013. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3</citedby><cites>FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpbi.12127$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpbi.12127$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,11562,27924,27925,46052,46476</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpbi.12127$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24119183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Julian K‐C.</creatorcontrib><creatorcontrib>Christou, Paul</creatorcontrib><creatorcontrib>Chikwamba, Rachel</creatorcontrib><creatorcontrib>Haydon, Hugh</creatorcontrib><creatorcontrib>Paul, Mathew</creatorcontrib><creatorcontrib>Ferrer, Merardo Pujol</creatorcontrib><creatorcontrib>Ramalingam, Sathishkumar</creatorcontrib><creatorcontrib>Rech, Elibio</creatorcontrib><creatorcontrib>Rybicki, Edward</creatorcontrib><creatorcontrib>Wigdorowitz, Andres</creatorcontrib><creatorcontrib>Yang, Dai‐Chang</creatorcontrib><creatorcontrib>Thangaraj, Harry</creatorcontrib><title>Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies</title><title>Plant biotechnology journal</title><addtitle>Plant Biotechnol J</addtitle><description>Summary Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.</description><subject>Biological Products - metabolism</subject><subject>Biotechnology</subject><subject>Biotechnology - economics</subject><subject>Biotechnology - methods</subject><subject>Developing Countries</subject><subject>Drug Design</subject><subject>Drug Industry - economics</subject><subject>Global Health</subject><subject>Humans</subject><subject>Intellectual Property</subject><subject>LDCs</subject><subject>Licenses</subject><subject>Licensing (technology)</subject><subject>low income</subject><subject>Molecular Farming - economics</subject><subject>Molecular Farming - methods</subject><subject>molecular pharming</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Plants - genetics</subject><subject>Plants - metabolism</subject><subject>Plants, Genetically Modified</subject><subject>Public health</subject><subject>R&amp;D</subject><subject>regulatory framework</subject><subject>Research &amp; development</subject><subject>resource‐poor</subject><subject>socially responsible licensing</subject><subject>Technology Transfer</subject><subject>Technology, Pharmaceutical - economics</subject><subject>Therapeutic targets</subject><subject>Vaccines</subject><issn>1467-7644</issn><issn>1467-7652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqN0U1LHDEYB_AgFdeXHvoFSqCXetg1yUxePLZSrSAoYs8hyT7RLJnJNJmx-O2b3bV7KAgmh4SHX_7w5EHoEyULWtfZYMOCMsrkHjqkrZBzKTj7sLu37QwdlbIihFHBxQGasZbSc6qaQ5TvwcRQQv-IxyfAzyZOgJPHQzT9iLsUwU3RZDw8mdxtVMIWevBh3DwYUso49HgJzxDTsBYuTf2YAxRs-iWGDvLjugwu9amr5RO0700s8PH1PEa_Ln88XPyc39xeXV98u5m7llE5B2upMJZKz8ECWXrnhSTENUo6YaVzlCvWMkYE48KZ1nNulVDAnHMcwDfH6Os2d8jp9wRl1F0oDmLtDNJUdP0d1fCWKPIeSpvmnClV6Zf_6CpNua-N6IYIWbfivKrTrXI5lZLB6yGHzuQXTYlez0zXmenNzKr9_Jo42Q6WO_lvSBWcbcGfEOHl7SR99_16G_kXUXWhMQ</recordid><startdate>201312</startdate><enddate>201312</enddate><creator>Ma, Julian K‐C.</creator><creator>Christou, Paul</creator><creator>Chikwamba, Rachel</creator><creator>Haydon, Hugh</creator><creator>Paul, Mathew</creator><creator>Ferrer, Merardo Pujol</creator><creator>Ramalingam, Sathishkumar</creator><creator>Rech, Elibio</creator><creator>Rybicki, Edward</creator><creator>Wigdorowitz, Andres</creator><creator>Yang, Dai‐Chang</creator><creator>Thangaraj, Harry</creator><general>John Wiley &amp; Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201312</creationdate><title>Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies</title><author>Ma, Julian K‐C. ; Christou, Paul ; Chikwamba, Rachel ; Haydon, Hugh ; Paul, Mathew ; Ferrer, Merardo Pujol ; Ramalingam, Sathishkumar ; Rech, Elibio ; Rybicki, Edward ; Wigdorowitz, Andres ; Yang, Dai‐Chang ; Thangaraj, Harry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biological Products - metabolism</topic><topic>Biotechnology</topic><topic>Biotechnology - economics</topic><topic>Biotechnology - methods</topic><topic>Developing Countries</topic><topic>Drug Design</topic><topic>Drug Industry - economics</topic><topic>Global Health</topic><topic>Humans</topic><topic>Intellectual Property</topic><topic>LDCs</topic><topic>Licenses</topic><topic>Licensing (technology)</topic><topic>low income</topic><topic>Molecular Farming - economics</topic><topic>Molecular Farming - methods</topic><topic>molecular pharming</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Plants - genetics</topic><topic>Plants - metabolism</topic><topic>Plants, Genetically Modified</topic><topic>Public health</topic><topic>R&amp;D</topic><topic>regulatory framework</topic><topic>Research &amp; development</topic><topic>resource‐poor</topic><topic>socially responsible licensing</topic><topic>Technology Transfer</topic><topic>Technology, Pharmaceutical - economics</topic><topic>Therapeutic targets</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Julian K‐C.</creatorcontrib><creatorcontrib>Christou, Paul</creatorcontrib><creatorcontrib>Chikwamba, Rachel</creatorcontrib><creatorcontrib>Haydon, Hugh</creatorcontrib><creatorcontrib>Paul, Mathew</creatorcontrib><creatorcontrib>Ferrer, Merardo Pujol</creatorcontrib><creatorcontrib>Ramalingam, Sathishkumar</creatorcontrib><creatorcontrib>Rech, Elibio</creatorcontrib><creatorcontrib>Rybicki, Edward</creatorcontrib><creatorcontrib>Wigdorowitz, Andres</creatorcontrib><creatorcontrib>Yang, Dai‐Chang</creatorcontrib><creatorcontrib>Thangaraj, Harry</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Plant biotechnology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Ma, Julian K‐C.</au><au>Christou, Paul</au><au>Chikwamba, Rachel</au><au>Haydon, Hugh</au><au>Paul, Mathew</au><au>Ferrer, Merardo Pujol</au><au>Ramalingam, Sathishkumar</au><au>Rech, Elibio</au><au>Rybicki, Edward</au><au>Wigdorowitz, Andres</au><au>Yang, Dai‐Chang</au><au>Thangaraj, Harry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies</atitle><jtitle>Plant biotechnology journal</jtitle><addtitle>Plant Biotechnol J</addtitle><date>2013-12</date><risdate>2013</risdate><volume>11</volume><issue>9</issue><spage>1029</spage><epage>1033</epage><pages>1029-1033</pages><issn>1467-7644</issn><eissn>1467-7652</eissn><abstract>Summary Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might be used to improve access to modern medicines, and improve health of the poor in developing countries and emerging economies. Although improving global health through molecular pharming has been discussed for at least two decades, little progress has actually been made. In this manuscript, a four point plan is described to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify and prioritise important drug targets that are relevant to the poor; (ii) to support research and development partners in low to middle income countries to develop local expertise, transfer technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable national regulatory frameworks to be developed in low to middle income countries; and (iv) to promote intellectual property management approaches that include socially responsible licensing. An existing case study is described to illustrate how this might be achieved.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>24119183</pmid><doi>10.1111/pbi.12127</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1467-7644
ispartof Plant biotechnology journal, 2013-12, Vol.11 (9), p.1029-1033
issn 1467-7644
1467-7652
language eng
recordid cdi_proquest_miscellaneous_1468354080
source Open Access: Wiley-Blackwell Open Access Journals
subjects Biological Products - metabolism
Biotechnology
Biotechnology - economics
Biotechnology - methods
Developing Countries
Drug Design
Drug Industry - economics
Global Health
Humans
Intellectual Property
LDCs
Licenses
Licensing (technology)
low income
Molecular Farming - economics
Molecular Farming - methods
molecular pharming
Pharmaceutical industry
Pharmaceuticals
Plants - genetics
Plants - metabolism
Plants, Genetically Modified
Public health
R&D
regulatory framework
Research & development
resource‐poor
socially responsible licensing
Technology Transfer
Technology, Pharmaceutical - economics
Therapeutic targets
Vaccines
title Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A05%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Realising%20the%20value%20of%20plant%20molecular%20pharming%20to%20benefit%20the%20poor%20in%20developing%20countries%20and%20emerging%20economies&rft.jtitle=Plant%20biotechnology%20journal&rft.au=Ma,%20Julian%20K%E2%80%90C.&rft.date=2013-12&rft.volume=11&rft.issue=9&rft.spage=1029&rft.epage=1033&rft.pages=1029-1033&rft.issn=1467-7644&rft.eissn=1467-7652&rft_id=info:doi/10.1111/pbi.12127&rft_dat=%3Cproquest_24P%3E1461339288%3C/proquest_24P%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4217-ebb16ab17f5ebe0dfcf6700c387c6b7cc158242206256ca4f55b868e2ccc5eef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3067676855&rft_id=info:pmid/24119183&rfr_iscdi=true